US2022204992A1PendingUtilityA1
Recombinant orf virus vector
Assignee: UNIV TUEBINGEN MEDIZINISCHE FAKULTAETPriority: Jul 20, 2015Filed: Mar 17, 2022Published: Jun 30, 2022
Est. expiryJul 20, 2035(~9 yrs left)· nominal 20-yr term from priority
C12N 2830/60C12N 2830/34C12N 15/86A61K 39/00A61K 2039/5154C12N 2710/24243A61P 37/04C12N 2840/10C12N 2015/8581C12N 2710/24222C12N 2710/24041C12N 2015/8572C12N 2710/24031C07K 14/005C12N 2800/107A61K 2039/53Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A nucleic acid molecule comprising a nucleotide sequence encoding an Orf virus (ORFV) promoter, wherein said nucleotide sequence is selected from the group consisting of: SEQ ID NO: 1 (P1) and SEQ ID NO: 2 (P2).
2 . The nucleic acid molecule of claim 1 , wherein the ORFV promoter is an early ORFV promoter.
3 . The nucleic acid molecule of claim 1 , which is a recombinant ORFV vector comprising a further nucleotide sequence encoding and expressing a foreign gene.
4 . The nucleic acid molecule of claim 3 , wherein said further nucleotide sequence is localized in at least one of insertion loci (IL) 1, 2 and 3, which are localized in the ORFV genome in the following regions:
IL 1
IL 2
IL 3
Restriction
HindIII fragment C,
HindIII fragment I/J,
HindIII fragment G/D,
fragment
KpnI fragment G,
KpnI fragment B,
KpnI fragment B,
BamHI fragment C/G,
BamHI fragment A,
BamHI fragment A,
EcoRI fragment B
EcoRI fragment A/E
EcoRI fragment D
and/or
Gene/ORF
006,
102,
114,
007 (dUTPase),
103
115,
008 (G1L-Ank),
116,
009 (G2L)
117 (GIF)
and/or
Nucleotid
nt 500 ± 100 to
nt 5.210 ± 100 to
nt 15.660 ± 100 to
position
nt 2.400 ± 600
nt 7.730 ± 100
nt 17.850 ± 100
5 . The nucleic acid molecule of claim 4 , wherein ORFV is of the strain D1701.
6 . The nucleic acid molecule of claim 3 , wherein the promoter is located at a position of nt 28±10 to nt−13±10, upstream in relation to the further nucleotide sequence encoding the foreign gene.
7 . The nucleic acid molecule of claim 4 , wherein at least in one of the IL 1, 2 or 3 there is inserted more than one further nucleotide sequence encoding and expressing a foreign gene.
8 . The nucleic acid molecule of claim 7 , wherein the number of the inserted further nucleotide sequences encoding and expressing a foreign gene is selected from the group consisting of: 2, 3, 4 and more than 4.
9 . The nucleic acid molecule of claim 3 , wherein the foreign gene is selected from the group consisting of the following antigens:
a viral antigen; a tumor antigen; a tumor associated antigen, including viral tumor associated antigen, including HPV selective viral tumor-associated antigen; a parasitic antigen; and a cytokine.
10 . The nucleic acid molecule of claim 9 , wherein the viral antigen is:
a rabies virus antigen, including glycoprotein (RabG); or an influenza A antigen selected from the group consisting of nucleoprotein (NP), hemagglutinin (HA) and neuraminidase (NA).
11 . The nucleic acid molecule of claim 9 , wherein the tumor antigen is a viral tumor associated antigen.
12 . The nucleic acid molecule of claim 11 , wherein the viral tumor associated antigen is an HPV selective viral tumor-associated antigen.
13 . The nucleic acid molecule of claim 9 , wherein the parasitic antigen is plasmodium antigen.Join the waitlist — get patent alerts
Track US2022204992A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.